title: Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.
abstract: The effects of the angiotensin converting enzyme (ACE) inhibitor enalapril on the proteinuria and degree of focal glomerular sclerosis hyalinosis (FSH) in chronic puromycin aminonucleoside nephropathy (PAN) were examined. Chronic PAN was induced in male Sprague-Dawley rats by seven subcutaneous injections of puromycin aminonucleoside (20 mg/kg) over 10 weeks (Groups I and II). Group II rats also received enalapril 10 mg/kg/day in the drinking water throughout the study (12 weeks). Group III rats served as age-matched controls. Proteinuria was similar in Groups I and II (35.5 +/- 9.7 versus 29.1 +/- 4.1 mg protein/mg creatinine, mean +/- SEM, P greater than 0.05). Serum creatinine remained unchanged in Group I, but rose from 0.7 +/- 0.04 to 1.2 +/- 0.1 mg/dl (mean +/- SEM, P less than 0.05) in Group II. FSH was 13.8% in Group I, 12.9% in Group II (P greater than 0.05), and 0.6% in Group III. There was no significant difference in glomerular lipid content and in immunofluorescence for rat albumin, fibrinogen, IgM, IgG, and C3 between Groups I and II. ACE activity was inhibited by 94% in serum, 83% in lungs, and 92% in kidneys; and blood pressure response to. Angiotensin I challenge was decreased by 50% in rats similarly treated with enalapril versus controls. In summary, proteinuria and glomerular sclerosis in this model are not affected by ACE inhibition.
authors.affiliation: Division of Nephrology, University of Utah Medical Center, Salt Lake City 84132.
authors.forename: G N
authors.initials: GN
authors.lastname: Marinides
authors.forename: G C
authors.initials: GC
authors.lastname: Groggel
authors.forename: A H
authors.initials: AH
authors.lastname: Cohen
authors.forename: T
authors.initials: T
authors.lastname: Cook
authors.forename: R L
authors.initials: RL
authors.lastname: Baranowski
authors.forename: C
authors.initials: C
authors.lastname: Westenfelder
authors.forename: W A
authors.initials: WA
authors.lastname: Border
mesh_terms: D000803:Angiotensin I / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000378:metabolism; D004656:Enalapril / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000201:enzymology / Q000473:pathology*; D008168:Lung / Q000201:enzymology; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D011507:Proteinuria; D011691:Puromycin / Q000031:analogs & derivatives*; D011692:Puromycin Aminonucleoside / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D011691:Puromycin; D011692:Puromycin Aminonucleoside; D004656:Enalapril; D000803:Angiotensin I; D003404:Creatinine; D007703:Peptidyl-Dipeptidase A